Klacid Contraindications

Hypersensitivity to macrolide antibiotic drugs/agents or to any of the excipients listed in Description.
Concomitant administration of clarithromycin and ergot alkaloids/ergotamine derivatives (e.g., ergotamine or dihydroergotamine) is contraindicated, as this may result in ergot toxicity (see Precautions and Interactions).
Concomitant administration of clarithromycin and oral midazolam is contraindicated (see Interactions).
Concomitant administration of clarithromycin and any of the following drugs is contraindicated: astemizole, cisapride, domperidone, pimozide and terfenadine as this may result in QT prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes (see Precautions and Interactions).
Clarithromycin should not be given to patients with history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes (see Precautions and Interactions).
Concomitant administration with ticagrelor or ranolazine is contraindicated.
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis. (See Interactions).
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in patients taking colchicine (see Precautions and Interactions).
Clarithromycin should not be given to/taken by patients with electrolyte disturbances (hypokalaemia or hypomagnesaemia, due to the risk of prolongation of the QT interval/time).
Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.
Film-coated tablet and Granules for oral suspension: Concomitant administration of clarithromycin and lomitapide is contraindicated (see Interactions).